Promotion of metastasis of thyroid cancer cells via NRP-2-mediated induction

Tu, Dom‐Gene; Chang, Wen‐Wei; Jan, Ming‐Shiou; Tu, Chi‐Wen; Lu, Yin-Che; Tai, Chien‐Kuo

doi:10.3892/ol.2016.5153

Cited by 19 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Progressive dedifferentiation of DTC is accompanied by loss of the sodium iodide symporter (NIS) that is required for iodine uptake. Poorly differentiated foci with loss of iodine avidity exhibit parallel development of F‐Fludeoxyglucose (FDG)‐PET positivity so that FDG‐PET‐positive disease is more likely to be refractory . Radioiodine refractory disease is far more common in older patients: those with large tumour burden and those with poorly differentiated subtypes such as tumours with Hurthle cell histology …”

Section: Defining Radioiodine Refractory Diseasementioning

confidence: 99%

“…17 VEGF is upregulated in DTC and one of its coreceptors, NRP-2, has been implicated in metastases through enhancement of invasion and motility in thyroid cancer cells. 18,19 Several studies have shown a correlation between VEGF receptor expression and metastasis in PTC. 18 Anti-angiogenic therapies have become established as treatments for advanced DTC.…”

Section: Introductionmentioning

confidence: 99%

“…18,19 Several studies have shown a correlation between VEGF receptor expression and metastasis in PTC. 18 Anti-angiogenic therapies have become established as treatments for advanced DTC. 11 The fibroblast growth factor signalling pathway also drives tumoirogenesis and has been successfully targeted by inhibitors (reviewed in Ref.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Gild

Topliss

Learoyd

et al. 2017

Clinical Endocrinology

View full text Add to dashboard Cite

Prognosis from differentiated thyroid cancer is worse when the disease becomes refractory to radioiodine. Until recently, treatment options have been limited to local therapies such as surgery and radiotherapy, but the recent availability of systemic therapies now provides some potential for disease control. Multitargeted kinase inhibitors (TKIs) including lenvatinib and sorafenib have been shown to improve progression-free survival in phase III clinical trials, but are also associated with a spectrum of adverse effects. Other TKIs have been utilized as "redifferentiation" agents, increasing sodium iodide symporter expression in metastases and thus restoring radioiodine avidity. Some patients whose disease progresses on initial TKI therapy will still respond to a different TKI and clinical trials currently in progress will clarify the best options for such patients. As these drugs are not inexpensive, care needs to be taken to minimize not only biological but also financial toxicity. In this review, we examine the basic biology of radioiodine refractory disease and discuss optimal treatment approaches, with specific focus on choice and timing of TKI treatment. This clinical field remains fluid, and directions for future research include exploring biomarkers and considering adjuvant TKI use in certain patient groups.

show abstract

Section: Defining Radioiodine Refractory Diseasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Gild

Topliss

Learoyd

et al. 2017

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Thus, stromal cells could modulate Decorin to control thyrocytes growth. Further, interactions for CYR61 (associated with Graves’ Disease (38)), LRP2 / Megalin (involved in thyroglobulin processing (39)) and NRP2 (associated with thyroid cancer metastasis (40)) were identified (Fig. 3C).…”

Section: Discussionmentioning

confidence: 98%

Single-cell transcriptome analysis reveals cell-cell communication and thyrocyte diversity in the zebrafish thyroid gland

Gillotay

Shankar

Eski

et al. 2020

Preprint

View full text Add to dashboard Cite

Single-cell transcriptome analysis reveals cell-cell communication and thyrocyte 1diversity in the zebrafish thyroid gland. 2 Abstract 16The thyroid gland regulates growth and metabolism via production of thyroid hormone in 17 follicles composed of thyrocytes. So far, thyrocytes have been assumed to be a 18 homogenous population. To uncover genetic heterogeneity in the thyrocyte population, 19 and molecularly characterize the non-thyrocyte cells surrounding the follicle, we 20 developed a single-cell transcriptome atlas of the zebrafish thyroid gland. The 6249-cell 21 atlas includes profiles of thyrocytes, blood vessels, lymphatic vessels, immune cells and 22 fibroblasts. Further, the thyrocytes could be split into two sub-populations with unique 23 transcriptional signature, including differential expression of the transcription factor 24 pax2a. To validate thyrocyte heterogeneity, we generated a CRISPR/Cas9-based 25 pax2a knock-in line, which demonstrated specific pax2a expression in the thyrocytes. 26However, a population of pax2a-low mature thyrocytes interspersed within individual 27 follicles could be distinguished, corroborating heterogeneity within the thyrocyte 28 population. Our results identify and validate transcriptional differences within the 29 nominally homogenous thyrocyte population. 30

show abstract

“…Beyond, VEGF-C-mediated invasion and migration of thyroid cancer cells required the expression of Nrp2. 16,17 Nrp2 intracellular domain interacts Roles of Nrp2/VEGF-C Axis in a Series of Recurrent Lymphangioma Yan et al 341…”

Section: Discussionmentioning

confidence: 99%

The Roles of Neuropilin 2/VEGF-C Axis in a Series of Recurrent Lymphangioma

et al. 2019

View full text Add to dashboard Cite

Objective Vascular endothelial growth factor (VEGF) and its receptor act as a major contributor to lymphangioma, but their role on nonrecurrent and recurrent lymphangiomas remain unclear. We aim to investigate those factors in the generation of recurrent lymphangioma. Materials and Methods Patients diagnosed with lymphangioma from January 2005 to December 2012 in our hospital were collected and divided into nonrecurrent and recurrent lymphangiomas. The clinical characteristics including age, sex, symptoms, location, and size of lymphangioma were collected. Surgical resection samples were collected for histology, protein and mRNA detection of VEGF-C, VEGF receptor-3 (VEGFR-3), and neuropilin 2 (Nrp2). Follow-ups including lymphangioma recurrent and the local symptoms such as ulcer were reviewed. Results A total of 80 patients aged from 5 months to 12 years were enrolled in this study, 51 patients had no recurrence and other 29 patients suffered from recurrent lymphangioma. There was no significant difference in demographic data and clinical characters between the two groups (p > 0.05). Immunohistochemistry staining showed that VEGFR-3 remained unchanged between nonrecurrent and recurrent lymphangiomas (p > 0.05), and VEGF-C and Nrp2 were significantly increased in recurrent lymphangioma compared with nonrecurrent lymphangioma (p < 0.05). The same expression trend was proved as detected by protein and mRNA levels. Conclusion The VEGF-C/Nrp2 axis was significantly increased in the recurrent lymphangioma, indicating that VEGF-C/Nrp2 targeted therapy may serve as a potential therapeutic strategy for recurrent lymphangioma.

show abstract

Promotion of metastasis of thyroid cancer cells via NRP-2-mediated induction

Abstract: Abstract. Tumor-node-metastasis is one of the leading causes of morbidity and mortality in thyroid cancer patients.

Cited by 19 publications

References 36 publications

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Clinical guidance for radioiodine refractory differentiated thyroid cancer

Single-cell transcriptome analysis reveals cell-cell communication and thyrocyte diversity in the zebrafish thyroid gland

The Roles of Neuropilin 2/VEGF-C Axis in a Series of Recurrent Lymphangioma

Contact Info

Product

Resources

About